phase i study of cd22 car-t therapy in patients with lbcl who have relapsed after cd19 car-t therapy
Published 1 year ago • 69 plays • Length 3:23Download video MP4
Download video MP3
Similar videos
-
2:32
phase i study of cd22-targeted car-t therapy in patients with cd19-negative b-all
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
2:20
risk factors for success or failure of cd19-directed car-t therapy in children with b-all
-
2:00
phase i study of cd5 car-t therapy manufactured with tkis in r/r t-all
-
3:18
evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
-
2:01
advances in cd22/cd19 car-t sequential therapy
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
3:42
factors associated with treatment response to cd19 car t-cell therapy in b-all
-
2:04
the evolving role of car-t therapy in cll
-
2:12
fully human anti-cd19 and cd22 bispecific tandem car-t
-
3:50
the safety and efficacy of auto1/22: a novel co-transduced cd19/22 car-t therapy for r/r all
-
2:26
clinical data for cd19-directed car t-cell products in all
-
1:58
car t-cell therapy and all: the current landscape
-
3:52
anti-cd22 car t-cells shift all into complete remission
-
1:17
cart19-be-01 trial: next-generation car t-cell therapy for cd19 r/r leukemia and lymphoma
-
3:06
repeat infusions of cd19 car-t
-
4:34
future perspectives in car-t therapy
-
1:28
assessment of car-t and tcr adverse events